Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

NeuroSense Therapeutics Says As Of August 20, 2025, ~20% Of People With ALS From The Company's Phase 2a Study, Including Those Continuing Under Compassionate Use, Remain On Primec For More Than 5.5 Years, Having Lived With Als For Over 7 Years; Across These Multi-Year Exposures, Treatment Remains Well Tolerated, With No New Safety Signals Observed To Date

Author: Benzinga Newsdesk | August 20, 2025 09:41am

Posted In: NRSN